90 related articles for article (PubMed ID: 10864136)
1. Reduction of the potential anticancer drug oracin in the rat liver in-vitro.
Szotáková B; Skálová L; Wsól V; Kvasniècková E
J Pharm Pharmacol; 2000 May; 52(5):495-500. PubMed ID: 10864136
[TBL] [Abstract][Full Text] [Related]
2. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Chem Biol Interact; 2003 Feb; 143-144():459-68. PubMed ID: 12604232
[TBL] [Abstract][Full Text] [Related]
3. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
Skálová L; Wsól V; Szotáková B; Kvasnicková E
Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
[TBL] [Abstract][Full Text] [Related]
4. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
5. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
Szotáková B; Skálová L; Jílek P; Buchta V; Wsól V
J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
[TBL] [Abstract][Full Text] [Related]
6. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Toxicology; 2004 May; 197(3):253-61. PubMed ID: 15033547
[TBL] [Abstract][Full Text] [Related]
7. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.
Wsól V; Skálová L; Szotáková B; Trejtnar F; Kvasnicková E
Chirality; 1999; 11(5-6):505-9. PubMed ID: 10368924
[TBL] [Abstract][Full Text] [Related]
9. Role of cytochrome P4501A in biotransformation of the potential anticancer drug oracin.
Szotáková B; Wsól V; Skálová L; Kvasnicková E
Exp Toxicol Pathol; 1999 Jul; 51(4-5):428-31. PubMed ID: 10445410
[TBL] [Abstract][Full Text] [Related]
10. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin.
Wsól V; Szotáková B; Skálová L; Cepková H; Kvasnicková E
Enantiomer; 2000; 5(3-4):263-70. PubMed ID: 11126866
[TBL] [Abstract][Full Text] [Related]
11. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
12. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.
Wsól V; Szotáková B; Kvasnicková E; Fell AF
J Chromatogr A; 1998 Feb; 797(1-2):197-201. PubMed ID: 9542111
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
14. 11Beta-hydroxysteroid dehydrogenase type 1: purification from human liver and characterization as carbonyl reductase of xenobiotics.
Maser E; Wsol V; Martin HJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):34-7. PubMed ID: 16343739
[TBL] [Abstract][Full Text] [Related]
15. Oral pharmacokinetics and in-vitro metabolism of metyrapone in male rats.
Murata H; Higuchi T; Otagiri M
J Pharm Pharmacol; 2016 Aug; 68(8):970-9. PubMed ID: 27265478
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation and detoxification of insecticidal metyrapone analogues by carbonyl reduction in the human liver.
Rekka EA; Soldan M; Belai I; Netter KJ; Maser E
Xenobiotica; 1996 Dec; 26(12):1221-9. PubMed ID: 9004452
[TBL] [Abstract][Full Text] [Related]
17. Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes.
Matsumoto K; Hasegawa T; Koyanagi J; Takahashi T; Akimoto M; Sugibayashi K
Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):127-35. PubMed ID: 24659525
[TBL] [Abstract][Full Text] [Related]
18. Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver.
Breyer-Pfaff U; Martin HJ; Ernst M; Maser E
Drug Metab Dispos; 2004 Sep; 32(9):915-22. PubMed ID: 15319331
[TBL] [Abstract][Full Text] [Related]
19. 11Beta-hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes.
Maser E
Cancer Res; 1998 Jul; 58(14):2996-3003. PubMed ID: 9679962
[TBL] [Abstract][Full Text] [Related]
20. Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro.
Skálová L; Nobilis M; Szotáková B; Kondrová E; Savlík M; Wsól V; Pichard-Garcia L; Maser E
Biochem Pharmacol; 2002 Jul; 64(2):297-305. PubMed ID: 12123751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
